An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Exclusion Criteria7

• Participants with a known hypersensitivity to sonelokimab or any of its excipients.
• Participants with a draining fistula count of ≥20 at the Screening Visit.
• Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
• Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
• Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
• Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
• Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.